Novo Nordisk A/s

Transtech Pharma, Inc.

János Tibor Kodra

Per Sauerberg

Patrick William Garibay

Thomas Hoeg-Jensen

Jesper F Lau

Peter Madsen

Adnan M M Mjalli

Lone Jeppesen

Robert Carl Andrews

Dharma Rao Polisetti

Palle Jakobsen

Thomas Kruse

Mustafa Guzel

Svend Havelund

Michael Ankersen

Anthony Murray

Ingrid Pettersson

Govindan Subramanian

Daniel Peter Christen

Ib Jonassen

Jacob Kofoed

Kjeld Madsen

Kalpathy Chidambareswaran Santhosh

Frantisek Hubalek

Tina Moeller Tagmose

Paw Bloch

Lars Linderoth

Birgit Wieczorek

Jane Spetzler

Tina Møller Tagmose

Per Vedsø

Thomas Børglum Kjeldsen

Jianhe Chen

Henning Thøgersen

Tine Glendorf

Maria Carmen Valcarce-Lopez

Jacob Sten Petersen

Lauge Schäffer

Niels Blume

Dorte Xenia Gram

Alice Ravn Madsen

Henning THØGERSEN

Salka Elbøl Rasmussen

Steffen Runge

An acylated insulin analogue wherein the insulin analogue comprises a lysine residue connected C-terminally to the A21 amino acid residue or a peptide residue of up to 4 amino acid residues comprising a lysine residue which peptide residue is connected C-terminally to the A21 amino acid residue, characterized in that an acyl moiety comprising an alkylene glycol moiety is attached to the lysine residue in the A22 position or attached to a lysine residue present in the peptide residue that is attached to the C terminal end of the A21 amino acid residue and wherein there is only one lysine (K, Lys) in the insulin analogue, can conveniently be administered pulmonary.

Insulin analogues with an acyl and alkylene glycol moiety

The present invention relates to insulin derivatives having a side chain attached either to the &#x3b1;-amino group of the N-terminal amino acid residue of the B chain or to the &#x3b5;-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.

Insulin derivatives

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes

The present invention relates to insulin derivatives having a side chain attached either to the -amino group of the N-terminal amino acid residue of the B chain or to the amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.

Growing community of inventors

København Ø, Denmark

János Tibor Kodra